QLT Inc. (USA)  

(Public, NASDAQ:QLTI)   Watch this stock  
Find more results for QLTI
+0.02 (0.45%)
Jan 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.39 - 4.58
52 week 3.35 - 7.09
Open 4.42
Vol / Avg. 56,179.00/299,902.00
Mkt cap 224.10M
P/E     -
Div/yield 3.92
EPS -0.50
Shares 51.19M
Beta 0.16
Inst. own 51%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -13.40% -9.14%
Return on average equity -13.92% -9.46%
Employees 37 -
CDP Score - -


Suite 250, 887 Great Northern Way
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. It develops QLT091001, a synthetic retinoid compound for the potential treatment of certain inherited retinal degenerative diseases. In September 2012,it sold all of its assets related to Visudyne to Valeant Pharmaceuticals International, Inc. (Valeant). It also sold Qcellus laser and certain other photodynamic therapy intellectual property, In April 2013, it sold its punctal plug drug delivery system (PPDS) technology (Technology) to Mati Therapeutics Inc. (Mati). It is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. It is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Interim Chief Executive Officer, Director
Age: 70
Bio & Compensation  - Reuters
Glen Ibbott Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Sukhi Jagpal Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
John W. Kozarich Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Jeffrey A. Meckler Independent Director
Age: 48
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
John C. Thomas Jr. Independent Director
Age: 60
Bio & Compensation  - Reuters